Medtronic Said Evolut TAVR Platform Outperforms Surgery With Sustained Valve Performance For Low-risk Patients At Four Years
Portfolio Pulse from Charles Gross
Medtronic plc (NYSE:MDT) announced four-year results from the Evolut Low Risk Trial, demonstrating exceptional outcomes and sustained valve performance of its Evolut transcatheter aortic valve replacement (TAVR) system. The system showed significantly better hemodynamics than surgical aortic valve replacement (SAVR) and reported consistently lower and diverging rates of death or disabling stroke versus state-of-the-art surgery, at four years.
October 24, 2023 | 6:25 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Medtronic's Evolut TAVR system has demonstrated superior performance over a four-year period, which could potentially boost the company's market position and stock value.
The positive results from the Evolut Low Risk Trial demonstrate the effectiveness of Medtronic's TAVR system, which could lead to increased demand for the product. This could potentially result in increased revenues for the company, positively impacting its stock value.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100